Yearly Archives: 2024
Utah Legislative Recap, Feb. 9, 2024
Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry. BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]
2024 Life Sciences Day on the Hill Recap
Utah’s vibrant life sciences industry was on full display February 7 as part of BioUtah’s “Life Sciences Day on the Hill”. The event, a collarboration with the Governor’s Office of Economic Opportunity, (GOEO) was held at the state capitol. 29 companies exhibited their innovative technologies in the capitol rotunda, which provided legislators the opportunity to […]
Eris Biotech accepted to Y Combinator
Eris Biotech accepted to Y Combinator
Clene Inc. Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation
This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2)
AdvaMed Announces New Chair of State Medtech Alliance
AdvaMed Announces New Chair of State Medtech Alliance
Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics
Funds will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic. LEHI, Utah, Jan. 31, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the completion […]
AI Utah Annouces Inaugural AI Utah 100 List
AI Utah Annouces Inaugural AI Utah 100 List
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health
Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health
Utah Innovation Fund invests $700k in local healthcare, life sciences startups
Utah Innovation Fund invests $700k in local healthcare, life sciences startups
